NATHANIEL BROOKS HORWITZ
Fondateur chez Avilar Therapeutics, Inc.
Profil
Nathaniel is a Principal on the Venture Team at RA Capital Management.
Nathaniel’s primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies.
He serves as a Board Director for GentiBio and New Equilibrium Bio.
He previously served as the Founder & CEO of Nivien Therapeutics.
Nathaniel graduated from Harvard University with a BA in Molecular and Cellular Biology.
Postes actifs de NATHANIEL BROOKS HORWITZ
| Sociétés | Poste | Début |
|---|---|---|
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Analyste en capital-investissement | 01/12/2020 |
GentiBio, Inc.
 GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Fondateur | 01/01/2020 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Fondateur | 01/01/2019 |
Superluminal Medicines Inc
 Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Directeur/Membre du Conseil | - |
Anciens postes connus de NATHANIEL BROOKS HORWITZ
| Sociétés | Poste | Fin |
|---|---|---|
Nivien Therapeutics Co.
 Nivien Therapeutics Co. Miscellaneous Commercial ServicesCommercial Services Nivien Therapeutics Co. is an American biotechnology company that operates in the field of biotechnology. The private company was founded by Nathaniel Brooks Horwitz. | Directeur Général | 31/12/2018 |
New Equilibrium Biosciences, Inc.
 New Equilibrium Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services New Equilibrium Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Boston, MA. | Directeur/Membre du Conseil | - |
Formation de NATHANIEL BROOKS HORWITZ
| Harvard University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
New Equilibrium Biosciences, Inc.
New Equilibrium Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services New Equilibrium Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Boston, MA. | Commercial Services |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Health Technology |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
Nivien Therapeutics Co.
Nivien Therapeutics Co. Miscellaneous Commercial ServicesCommercial Services Nivien Therapeutics Co. is an American biotechnology company that operates in the field of biotechnology. The private company was founded by Nathaniel Brooks Horwitz. | Commercial Services |
Superluminal Medicines Inc
Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Health Technology |
